← Evidence map

ArticleMedComm2026

Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer.

Shiyue Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer. | OpenQuestion